May 13, 2020 / 10:03 PM / 20 days ago

BRIEF-Liminal BioSciences Says Net Loss From Continuing Operations Was $27.7 Million

May 13 (Reuters) - Liminal BioSciences Inc:

* LIMINAL BIOSCIENCES REPORTS Q1 2020 RESULTS

* LIMINAL BIOSCIENCES INC - DURING Q1, COVID-19 DID NOT HAVE A MATERIAL IMPACT ON UNDERLYING BUSINESS OPERATIONS OR FINANCIAL CONDITION

* LIMINAL BIOSCIENCES INC - CONTINUE TO PLAN FOR COMMENCEMENT OF A PHASE 1 MULTI-ASCENDING DOSE STUDY FOR FEZAGEPRAS DURING 2020

* LIMINAL BIOSCIENCES - WILL NOT BE PROVIDING FURTHER GUIDANCE ON NATURE AND TIMING OF FUTURE TRIALS FOR FEZAGEPRAS GIVEN POTENTIAL IMPACT OF COVID-19

* LIMINAL BIOSCIENCES INC QTRLY REVENUES WERE $1.1 MILLION VERSUS $2.3 MILLION

* LIMINAL BIOSCIENCES INC QTRLY NET LOSS FROM CONTINUING OPERATIONS WAS $27.7 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below